Gilead Sciences (NASDAQ:GILD) Given New $155.00 Price Target at Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD) had its price objective hoisted by investment analysts at Cantor Fitzgerald from $135.00 to $155.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 5.28% from the stock’s previous close.

A number of other brokerages also recently commented on GILD. Daiwa Securities Group increased their price target on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Argus upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Wolfe Research raised their price target on shares of Gilead Sciences from $150.00 to $155.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 28th. Leerink Partners lifted their price target on shares of Gilead Sciences from $114.00 to $146.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. Finally, TD Cowen increased their price objective on shares of Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Twenty-five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $140.08.

Gilead Sciences Price Performance

GILD opened at $147.23 on Wednesday. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $153.13. The firm has a market cap of $182.67 billion, a price-to-earnings ratio of 22.83, a PEG ratio of 0.80 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a fifty day simple moving average of $128.39 and a 200 day simple moving average of $121.53.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts expect that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In related news, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the sale, the director owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. This represents a 15.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 319,391 shares of company stock valued at $44,141,101 in the last ninety days. 0.27% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. GoalVest Advisory LLC lifted its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new stake in Gilead Sciences in the third quarter worth approximately $26,000. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at about $27,000. Ares Financial Consulting LLC bought a new position in Gilead Sciences in the 4th quarter worth $28,000. Finally, Financial Consulate Inc. raised its stake in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat: Gilead reported EPS of $1.86 and revenue of ~$7.9B, topping consensus and driven by strong HIV and liver‑disease sales. Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth …
• Positive Sentiment: Dividend raised: Board approved a 3.8% increase to $0.82 quarterly ($0.82 payable Mar 30; ex‑div Mar 13), supporting income investors (yield ~2.2%). Gilead Sciences Announces 3.8-Percent Increase in First Quarter 2026 Dividend
• Positive Sentiment: Pipeline and launches: Management highlighted Yeztugo launch momentum and possible approvals later this year (two cancer therapies plus an additional HIV option), which could drive future growth. Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
• Neutral Sentiment: Full Q4 call transcript now available for detail on revenue mix and margin drivers — useful for investors digging into product‑level trends. Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts’ metric review: Several outlets note Gilead beat top‑ and bottom‑line estimates but some year‑over‑year metrics are mixed — monitor product mix and FX effects in the slides. Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–8.85 and revenue $29.6–30.0B sit at or below consensus (EPS ~8.69; revenue ~30.1B), prompting the after‑hours selloff. Expect near‑term pressure until guidance proves conservative or growth catalysts materialize. Gilead 2026 outlook short of Wall Street view, shares dip

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.